Literature DB >> 28684446

Persistence of exhaustion in cured hep C.

David E Kaplan1.   

Abstract

Entities:  

Year:  2017        PMID： 28684446      PMCID： PMC5501153          DOI： 10.1182/blood-2017-05-786368

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Expansion of functionally anergic CD21-/low marginal zone-like B cell clones in hepatitis C virus infection-related autoimmunity.

Authors:  Benjamin Terrier; Florence Joly; Thomas Vazquez; Philippe Benech; Michelle Rosenzwajg; Wassila Carpentier; Marlène Garrido; Pascale Ghillani-Dalbin; David Klatzmann; Patrice Cacoub; David Saadoun
Journal:  J Immunol       Date:  2011-11-14       Impact factor: 5.422

2.  Cutting Edge: B Cell-Intrinsic T-bet Expression Is Required To Control Chronic Viral Infection.

Authors:  Burton E Barnett; Ryan P Staupe; Pamela M Odorizzi; Olesya Palko; Vesselin T Tomov; Alison E Mahan; Bronwyn Gunn; Diana Chen; Michael A Paley; Galit Alter; Steven L Reiner; Georg M Lauer; John R Teijaro; E John Wherry
Journal:  J Immunol       Date:  2016-07-18       Impact factor: 5.422

3.  Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset.

Authors:  Edgar D Charles; Claudia Brunetti; Svetlana Marukian; Kimberly D Ritola; Andrew H Talal; Kristen Marks; Ira M Jacobson; Charles M Rice; Lynn B Dustin
Journal:  Blood       Date:  2011-03-18       Impact factor: 22.113

4.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Authors:  James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts
Journal:  JCI Insight       Date:  2017-04-20

5.  Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia.

Authors:  Martina Del Padre; Laura Todi; Milica Mitrevski; Ramona Marrapodi; Stefania Colantuono; Massimo Fiorilli; Milvia Casato; Marcella Visentini
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

6.  Hepatitis C viraemia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B cells.

Authors:  L-Y Chang; Y Li; D E Kaplan
Journal:  J Viral Hepat       Date:  2016-12-20       Impact factor: 3.728

Review 7.  Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: A case series.

Authors:  Scott L Cornella; Jonathan G Stine; Virginia Kelly; Stephen H Caldwell; Neeral L Shah
Journal:  Postgrad Med       Date:  2015-03-07       Impact factor: 3.840

8.  B cells expressing the transcription factor T-bet drive lupus-like autoimmunity.

Authors:  Kira Rubtsova; Anatoly V Rubtsov; Joshua M Thurman; Johanna M Mennona; John W Kappler; Philippa Marrack
Journal:  J Clin Invest       Date:  2017-02-27       Impact factor: 14.808

9.  Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expressing memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis.

Authors:  Maurizio Carbonari; Elisabetta Caprini; Tiziana Tedesco; Francesca Mazzetta; Valeria Tocco; Milvia Casato; Giandomenico Russo; Massimo Fiorilli
Journal:  J Immunol       Date:  2005-05-15       Impact factor: 5.422

10.  Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus-associated mixed cryoglobulinemia.

Authors:  Edgar D Charles; Michael I M Orloff; Eiko Nishiuchi; Svetlana Marukian; Charles M Rice; Lynn B Dustin
Journal:  Arthritis Rheum       Date:  2013-09
  10 in total
  1 in total

1.  HBV induces inhibitory FcRL receptor on B cells and dysregulates B cell-T follicular helper cell axis.

Authors:  Bhawna Poonia; Natarajan Ayithan; Madhuparna Nandi; Henry Masur; Shyam Kottilil
Journal:  Sci Rep       Date:  2018-10-17       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.